Recent advances include copper‐based nanomedicines that can induce cuproptosis in cancer both in vitro and in vivo.[132] A key therapeutic concept is to combine these metal‐enhancing agents with drugs that cripple cellular defense mechanisms—such as inhibitors of GPX4 or system Xc− for ferroptosis—to create a synthetic lethal therapeutic window and overcome resistance. This evidence concerns the gene GPX4 and cancer.